CHICAGO (Reuters) - Colorectal cancer patients treated with a follow-up round of Avastin fare better than those given chemotherapy alone after their disease has worsened, according to results of a large clinical trial. Avastin, sold by Roche, is approved as a first-line or second-line treatment for colorectal cancer, but not for both. Sales of the drug, also known as bevacizumab, totaled $5.3 billion Swiss francs ($5.5 billion) last year. ... Courtesy of Yahoo News
No comments:
Post a Comment